

Berna Biotech AG

[View the current Berna Biotech AG Page on BioPortfolio.com](http://www.bioportfolio.com/bi corporate/19286-Berna+Biotech+AG.html)

(<http://www.bioportfolio.com/bi corporate/19286-Berna+Biotech+AG.html>)

Contact Details:

Auberg 6
Basel

Tel: 061 270 80 20

Fax: 061 270 80 21

Email: switzerland@bernabiotech.ch

CH - 4051

Switzerland

Berna Biotech Schweiz (Sitz in Basel) ist eine Filiale der Berna Biotech AG in Bern-Bümpliz. Sie ist verantwortlich für Marketing und Verkauf der Berna-Produkte in der Schweiz.

Berna Biotech wurde 1898 gegründet und hiess damals "Schweiz. Serum- & Impfinstitut Bern". Von Anfang an waren Infektionskrankheiten, deren Prävention und Behandlung Gegenstand intensiver wissenschaftlicher Forschung. Berna Biotech trug - und trägt - mit ihren Impfstoffen massgeblich dazu bei, Menschen auf allen Kontinenten vor gefährlichen Infektionskrankheiten wie Wundstarrkrampf, Diphtherie, Masern, Typhus, Grippe, Hepatitis A oder Hepatitis B zu schützen

Recent Publications by Berna Biotech AG:



- [Eleven years of Inflexal V-a virosomal adjuvanted influenza vaccine.](#)
Since the introduction to the Swiss market in 1997, Crucell (former Berna... 14th August, 2009
Berna Biotech AG, Rehhagstrasse 79, 3018 Berne, Switzerland.- *Vaccine*. 2009 Jul 16;27(33):4381-7.
Epub 2009 May 29. ([DOI Direct Link](#))
- [Use of attenuated bacteria as delivery vectors for DNA vaccines.](#)
Live, attenuated bacterial vaccines (LBV) are promising candidates for the... 31st March, 2007
Berna Biotech AG, Rehhagstrasse 79, CH-3018 Berne, Switzerland.- *Expert Rev Vaccines*. 2007
Feb;6(1):97-110. ([DOI Direct Link](#))
- [Haemolysin A and listeriolysin--two vaccine delivery tools for the induction of cell-mediated immunity.](#)
Haemolysin A of Escherichia coli and listeriolysin of Listeria... 8th October, 2003
Vaccine Research, Berna Biotech AG, Rehhagstr. 79, CH-3018, Bern,- *Int J Parasitol*. 2003
May;33(5-6):495-505.

Press Releases on Berna Biotech AG:

North Carolina Based Cromoz Inc. Launches Carbon Nanotechnology for Target Drug Delivery System in Cancer Treatment in Hyderabad, India	27th November, 2009	Cromoz Inc.	DURHAM, N.C., Nov. 27 /PRNewswire/ -- Cromoz Inc., located in Research Triangle Park, will initiate water-soluble carbon nanotube-based cancer drug delivery system in Hyderabad, India. The water
U.S. Food And Drug Administration (FDA) Grants Traditional Approval for INTELENCE(R) (etravirine)	25th November, 2009	Tibotec Therapeutics	- Severe, potentially life-threatening, and fatal skin reactions have been reported in patients taking INTELENCE. These include cases of Stevens-Johnson syndrome, toxic
Despite Managed Care Obstacles, Interest and Anticipated Use of Centocor Ortho-Biotech's New Psoriasis Agent Stelara (ustekinumab) is High	25th November, 2009	BioTrends Research Group, Inc.	EXTON, Pa., Nov. 25 /PRNewswire/ -- BioTrends Research Group, Inc. released Wave 1 of its LaunchTrends(TM): Stelara report, the first in a multi-phase syndicated market research project tracking the
Sinovac Establishes Joint Venture to Expand Human-Use Vaccine Development and Manufacturing Capabilities	25th November, 2009	Sinovac Biotech Ltd.	BEIJING, Nov. 25 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (Nasdaq: SVA), a leading developer and provider of vaccines, announced today that it executed a joint venture (JV) agreement to establish
Reportlinker Adds Cell/Tissue Culture Supplies - A Global Market Perspective	25th November, 2009	Reportlinker	NEW YORK, Nov. 25 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue: Cell/Tissue Culture Supplies - A Global Market Perspective http://www

BioCorporate Profiles - upgrade to a full profile

BioPortfolio's BioCorporate full profiles offers your organization the opportunity to increase internet traffic to

your corporate web site and enhance awareness of your business, technology, products and services. BioCorporate profiles are dynamic and are updated weekly with new information sourced from core information resources: publications, clinical trials, patents and global news.

Why you should upgrade your BioPortfolio BioCorporate profile:

- the ability to amend and add information on products and services to your profile using a membership username and password
- the option to add a corporate logo
- the creation of high value URL links back to your organization's website which will improve search engine ranking - resulting in increased site traffic
- the option have your press releases published on BioPortfolio and distributed via our BioNewsCast service
- an enhanced BioCorporate profile will also improve your exposure on BioPortfolio's related service InDepth and GeneDB

The annual cost is \$995.00 for established organizations and \$495.00 for organizations less than 12 months old.

Resources from the [NCBI](#) used in this document, [NCBI's standard disclaimer applies](#).

Nothing in this document should be used in place of personal medical advice from your own qualified medical practitioner. See BioPortfolio.com [User Agreement](#)

Send comments and feedback to:

Peter Barfoot Managing Director, BioPortfolio Ltd.

UK Tel: (+44) 1300 321501

USA Voicemail and Fax: (+1) 415 680 2472

[Peter Barfoot peter.barfoot@bioportfolio.com](mailto:peter.barfoot@bioportfolio.com)

All rights reserved. All other trademarks recognized.

BioPortfolio Limited is registered in England & Wales at Stafford House, 10 Prince of Wales Road, Dorchester, Dorset, DT1 1PW, UK. No.3312883 VAT No. GB 744 6483 10

Copyright 1997-2009 - BioPortfolio Limited.

